Navigation Links
Zoledronic acid shows long-term benefit in survivorship for premenopausal ER-positive breast cancer
Date:12/7/2011

SAN ANTONIO Researchers have proven the continuing effectiveness of treating patients with estrogen receptor-positive premenopausal breast cancer with adjuvant zoledronic acid in addition to adjuvant endocrine treatment including ovarian function suppression.

Data from the Austrian Breast & Colorectal Cancer Study Group (ABCSG-12), reported at the 2011 CTRC-AACR San Antonio Breast Cancer Symposium, held Dec. 6-10, 2011, confirmed and extended data reported at 48 months and 62 months of follow-up. Now at 84 months of follow-up, patients are experiencing drastically fewer recurrences of breast cancer and improved rates of survivorship without toxic side effects.

"We have confirmed what this trial showed initially, which was both exciting and surprising," said Michael Gnant, M.D., professor of surgery and president of the ABCSG at the Medical University of Vienna. "The continued success of this treatment means we can intervene early and still observe persistence of the benefit of treatment."

In the four-arm trial, researchers randomly assigned 1,803 premenopausal patients with early-stage, estrogen receptor (ER)-positive breast cancer to receive tamoxifen or anastrazole or each of these two treatments with zoledronic acid for three years. In the initial report, presented in 2008, Gnant and his colleagues reported significantly improved disease-free survival.

The most recent long-term data, at 84 months after treatment, revealed a 28 percent reduced risk for recurrence and a 36 percent reduction in risk for death among patients treated with zoledronic acid. Also, no patients experienced osteonecrosis of the jaw or renal failure thus, Gnant said, proving the safety of the treatment seven years later.

Researchers also found that patients aged older than 40 years with presumed complete ovarian blockade had a 34 percent reduced risk for recurrence and a 44 percent reduced risk for death. They found no significant survival benefits among patients aged younger than 40 years.

Gnant and his team said these data, considered with previously demonstrated bone-protective effects of zoledronic acid, suggest that adding zoledronic acid to adjuvant endocrine therapy including ovarian function suppression should be considered for premenopausal women with ER-positive early breast cancer.


'/>"/>

Contact: Jeremy Moore
Jeremy.Moore@aacr.org
215-446-7109
American Association for Cancer Research
Source:Eurekalert

Related medicine news :

1. Zoledronic acid reduces the recurrence of breast cancer in post-menopausal women
2. Bone drug zoledronic acid may help prevent spread of early lung cancer
3. Novel approach to treating breast cancer shows great promise
4. Heads up Kobe Bryant! Research shows that trying for another 3-pointer is a mistake
5. Study shows many older Floridians have no backup plan after hanging up their keys
6. When babies awake: New study shows surprise regarding important hormone level
7. Risk factors for CCSVI are similar to risk factors for developing MS, UB study shows
8. Study shows hospice caregivers need routine care interventions
9. Study shows medical marijuana laws reduce traffic deaths
10. Tools for predicting diabetes exist but are not used, research shows
11. LSUHSC research shows Rx with hyperbaric oxygen improved TBI and PTSD in vets
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/12/2017)... WILMINGTON, Del. (PRWEB) , ... October 12, 2017 ... ... technology and advisory services for healthcare compliance program management, will showcase a range ... and National Association for Assisted Living (NCAL) Convention and Expo to be held ...
(Date:10/12/2017)... (PRWEB) , ... October 12, 2017 , ... IsoComforter, Inc. ... products, announced today the introduction of an innovative new design of the shoulder pad. ... so you get maximum comfort while controlling your pain while using cold therapy. By ...
(Date:10/12/2017)... ... 2017 , ... Dr. Parsa Mohebi, the Los Angeles based ... the newly revamped Cosmetic Town journal section, featuring articles written by ... as Follicular Unit Extraction (FUE). , Dr. Mohebi says “I enjoy ...
(Date:10/12/2017)... ... October 12, 2017 , ... Women-owned and ... 2017 Best and Brightest in Wellness® by Best and Brightest. OnSite Wellness will ... Friday, Oct. 20 from 7:30 a.m. to 2 p.m. at the Henry Autograph ...
(Date:10/12/2017)... , ... October 12, 2017 , ... ... at the University of California Berkeley, and other leading institutions in announcing the ... power of institutions to change the way animals are raised for food. , ...
Breaking Medicine News(10 mins):
(Date:10/10/2017)... , Oct. 10, 2017   West Pharmaceutical ... innovative solutions for injectable drug administration, today shared the ... ID Adapter for improving the intradermal administration of polio ... Skin Vaccination Summit in May 2017 by Dr. ... Polio Department, World Health Organization (WHO), and recently published ...
(Date:10/4/2017)... Centers for Disease Control and Prevention (CDC), influenza vaccination should take ... communities across Massachusetts , Connecticut , ... through the end of the month. *Some exclusions apply ... ... by the end of October, according to the Centers for Disease Control ...
(Date:10/2/2017)...  AllianceRx Walgreens Prime, the combined central specialty pharmacy ... benefit manager Prime Therapeutics LLC (Prime), today officially began ... unveiling of new signage at its headquarters in ... a few other company-owned facilities across the country. This ... of whom will begin to see the AllianceRx Walgreens ...
Breaking Medicine Technology: